Angelina Jolie raised global awareness of breast cancer, genetic testing and pre-emptive medical procedures when she revealed her decision to have a double mastectomy five months ago. Now her surgeon says that by going public with her ordeal, the actress has saved lives.
“I’m seeing in my practice already women who are saying, ‘I was inspired by that to get gene testing,'” said Dr. Jay Orringer, the Beverly Hills, Calif., surgeon who performed Jolie’s breast reconstruction, in an interview with the New York Daily News this past weekend. “I think it’s going to have a tremendously lasting impact.”
The National Society of Genetic Counselors did indeed notice an immediate “Jolie Effect” as soon as the actress publicly revealed her medical situation.
On the day Jolie’s op-ed about her decision and treatment appeared in The New York Times, visits to the society’s “Find a Genetic Counselor” online tool jumped by 86 percent, according to the society, and Cancer.gov’s Preventive Mastectomy Fact Sheet, which typically receives fewer than 200 page views per day, according to the organization, jumped to more than 69,000 page views.
Dr. Mehra Golshan, director of Breast Surgical Services at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston, said he agreed with Orringer that Jolie’s story might help save lives by raising awareness of the disease, but he worries about a downside.
He said his practice had seen a 50 percent increase in requests for genetic counseling, which is positive, he said, but he believes patients sometimes act out of fear or before they have all the information they need to make informed choices.
“We have always gone through a complete family history with our breast cancer patients. The difference is now patients come in saying they want to be tested and meet with a reconstructive surgeon even before they go through an evaluation,” Golshan said.
Golshan emphasized the importance of meeting with a genetic counselor to evaluate cancer risk before pushing forward with testing or treatment. He said he didn’t recommend testing for people without a family history of breast or ovarian cancer. Because test results aren’t always conclusive, they can lead to additional testing and the potential for unnecessary stress and cost, he said.
He also worried that instead of fighting to save their breasts as they did in the past, many women are choosing to remove them at the slightest hint of cancer, even if they don’t carry one of the high-risk genetic mutations associated with a sharp increase in breast and ovarian cancer.
“We are now getting requests for contralateral prophylactic mastectomy surgery from patients who don’t have a genetic predisposition for breast cancer and who won’t necessarily benefit from breast removal,” he said.
Women like Jolie, who have inherited a harmful mutation of either the BRACA1 or BRCA2 gene are about five times more likely than average to develop breast cancer, and up to 40 percent more likely to develop ovarian cancer, according to the National Cancer Institute. Experts increasingly believe that removing as much breast tissue as possible can be a lifesaving strategy.